Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Summit Therapeutics Inc’s stock clocked out at $26.66, down -0.30% from its previous closing price of $26.74. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 1.57 million shares were traded. SMMT stock price reached its highest trading level at $27.6899 during the session, while it also had its lowest trading level at $26.26.
Ratios:
To gain a deeper understanding of SMMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.63 and its Current Ratio is at 10.63. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on July 01, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On June 11, 2025, Leerink Partners started tracking the stock assigning a Underperform rating and target price of $12.
Citigroup Upgraded its Neutral to Buy on March 26, 2025, whereas the target price for the stock was revised from $23 to $35.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 19799474176 and an Enterprise Value of 19444609024.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.05, which has changed by 1.5009382 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $8.88. The 50-Day Moving Average of the stock is 14.06%, while the 200-Day Moving Average is calculated to be 25.08%.
Shares Statistics:
It appears that SMMT traded 3.98M shares on average per day over the past three months and 2391930 shares per day over the past ten days. A total of 741.61M shares are outstanding, with a floating share count of 111.44M. Insiders hold about 84.99% of the company’s shares, while institutions hold 13.22% stake in the company. Shares short for SMMT as of 1752537600 were 28557957 with a Short Ratio of 7.17, compared to 1749772800 on 30530476. Therefore, it implies a Short% of Shares Outstanding of 28557957 and a Short% of Float of 24.48.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Summit Therapeutics Inc (SMMT) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.27 and -$0.34 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.38, with 7.0 analysts recommending between -$0.3 and -$0.47.
Revenue Estimates
Based on 11 analysts’ estimates, the company’s revenue will be $16.14M in the next fiscal year. The high estimate is $159.92M and the low estimate is -$42.88M.
